Of the primary brain tumors, intracranial neoplasms that originate from neuroglial cells are the most frequent and are collectively known as gliomas. The most malignant form is the glioblastoma multiforme (GBM), which is composed of poorly differentiated neoplastic cells with areas of vascular proliferation and/or necrosis. Surgery and radiotherapy and/or chemotherapy are the main treatment modalities currently available to patients with primary brain tumors. The continued dismal prognosis of glioblastomas has led to an increased focus on new treatment principles for the disease, including, but not limited to, gene therapy (thymidine-kinase suicide therapy, antisense inhibition of tumor growth factor receptors, and conditionally lethal viral vectors), immunotherapy (antibody, tumor cell vaccines, and adoptive transfer of activated lymphocytes), and antiangiogenesis approaches. This chapter focuses on the current use and limitations of various animal models to study glioma growth and progression, and the potential use of cell-based therapies toward the disease. It also highlights some important areas of research related to cell therapies of GBMs.
|Title of host publication||Cellular Transplantation|
|Subtitle of host publication||From Laboratory to Clinic|
|Number of pages||8|
|Publication status||Published - 2007|